Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZIO-101 in Advanced Blood and Bone Marrow Cancers
NCT00421213Phase 2Terminated
- Sponsor
- Alaunos Therapeutics
- Start
- Dec 2006
- Primary completion
- Jun 2009
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darinaparsin in hematologic neoplasm, bone marrow neoplasm, non-Hodgkin lymphoma (NHL) and 1 more, sponsored by Alaunos Therapeutics. Primary endpoint: Response Rate at 6 months. Started Dec 2006; status: terminated.
02
Drugs
darinaparsin
03
Conditions
hematologic neoplasmbone marrow neoplasmnon-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00421213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00421213.